NCT04049448 Phase 2 Completed
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis Study sponsor: Abivax S.A. · ABVX
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2023-01-23 Actual
Enrollment · participants 40 Actual
Source updated 2025-11-17 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2025-11-17 · 1 field changed
Primary completion date Recorded edit − Previous value 2021-04-30
+ Updated value 2023-01-23
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology